NZ company resurrects cancer wand

A failed Australian biotechnology developer’s cervical cancer screening technology has been resurrected by an Auckland company that will list on the New Zealand sharemarket this week.

Parnell-based TruScreen says its medical device – a digital wand that uses electrical and optical signals to detect cancerous and pre-cancerous tissue – has solid growth prospects in emerging markets such as China and Indonesia, where women often lack access to screening programmes.

Read more